Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

Phase 2

Terminated

Conditions: Dermatitis, Atopic

Interventions: Drug: Spesolimab

First Posted Date: 2019-09-11

Last Posted Date: 2022-07-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT04086121

Locations: 🇺🇸
The Indiana Clinical Trials Center, PC, Plainfield, Indiana, United States
🇯🇵
Tokyo Medical University Hachioji Medical Center, Tokyo, Hachioji, Japan
🇺🇸
Clinical Physiology Associates, Fort Myers, Florida, United States

and more 7 locations

TARA Working Prototype Engagement Evaluation: Feasibility Study

Not Applicable

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Device: Digital Behaviour Change Intervention

First Posted Date: 2019-09-11

Last Posted Date: 2020-09-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT04085302

Locations: 🇺🇸
Medullan, Somerville, Massachusetts, United States

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1356225
Drug: Placebo

First Posted Date: 2019-08-22

Last Posted Date: 2022-12-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 65

Registration Number: NCT04065295

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 894416 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 894416
Drug: Rifampicin

First Posted Date: 2019-08-19

Last Posted Date: 2023-08-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT04060719

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

Phase 2

Terminated

Conditions: Cystic Fibrosis

Interventions: Drug: Placebo
Drug: BI 1265162

First Posted Date: 2019-08-16

Last Posted Date: 2021-06-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 52

Registration Number: NCT04059094

Locations: 🇧🇪
Brussels - UNIV UZ Brussel, Brussels, Belgium
🇫🇷
HOP Arnaud de Villeneuve, Montpellier, France
🇫🇷
HOP Robert Debré, Paris, France

and more 23 locations

A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis

Phase 2

Completed

Conditions: Palmoplantar Pustulosis (PPP)

Interventions: Drug: Spesolimab
Drug: Placebo

First Posted Date: 2019-07-11

Last Posted Date: 2022-07-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 152

Registration Number: NCT04015518

Locations: 🇯🇵
Shiga University of Medical Science Hospital, Shiga, Otsu, Japan
🇯🇵
Teikyo University Hospital, Tokyo, Itabashi-ku, Japan
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 85 locations

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1323495 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1323495
Drug: Itraconazole

First Posted Date: 2019-07-08

Last Posted Date: 2024-02-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT04011241

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium + Olodaterol
Drug: LAMA
Drug: Other LABA/LAMA

First Posted Date: 2019-07-08

Last Posted Date: 2022-06-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1617

Registration Number: NCT04011475

Locations: 🇨🇳
Ditmanson Medical Foundation Chia - Yi Christian Hospital, Chia YI City, Taiwan
🇨🇳
CGMH Chia YI, Chia YI City, Taiwan
🇨🇳
CGMH Kaohsiung, Kaohsiung City, Taiwan

and more 9 locations

Re-usable Respimat® Soft MistTM Inhaler Study

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Respimat

First Posted Date: 2019-07-08

Last Posted Date: 2021-03-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 262

Registration Number: NCT04011735

Locations: 🇳🇴
Svelvik Legesenter, Svelvik, Norway
🇩🇰
Hvidovre Hospital, Hvidovre, Denmark
🇧🇪
Clinique Notre-Dame de Grâce, Gosselies, Belgium

and more 17 locations

A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

Phase 1

Terminated

Conditions: Macular Degeneration

Interventions: Drug: BI 754132

First Posted Date: 2019-06-28

Last Posted Date: 2023-09-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT04002310

Locations: 🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸
Retina Specialty Institute, Pensacola, Florida, United States
🇺🇸
Center for Retina and Macular Disease, Winter Haven, Florida, United States

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy